AEON Biopharma, Inc.

AEON Biopharma, Inc. (Nasdaq: AEON) is a clinical-stage biopharmaceutical company that completed its de-SPAC business combination with Priveterra Acquisition Corp, a blank-check vehicle that conducted its initial public offering in 2021 under sponsor Priveterra Sponsor LLC. The combined company operates in the healthcare and biotechnology sector, developing botulinum toxin-based therapeutics targeting neuromuscular and movement disorders, including cervical dystonia. The company filed an 8-K with the Securities and Exchange Commission on July 5, 2023, under accession number 0001104659-23-078184, reflecting a material corporate event following its transition to public-company status. To access the full filing history, sponsor background, and deal analytics for AEON and the broader SPAC universe, sign up for a SpacDesk account at spacdesk.com.